TY  - JOUR
AU  - Slavc, Irene
AU  - Mayr, Lisa
AU  - Stepien, Natalia
AU  - Gojo, Johannes
AU  - Aliotti Lippolis, Maria
AU  - Azizi, Amedeo A
AU  - Chocholous, Monika
AU  - Baumgartner, Alicia
AU  - Hedrich, Cora S
AU  - Holm, Stefan
AU  - Sehested, Astrid
AU  - Leblond, Pierre
AU  - Dieckmann, Karin
AU  - Haberler, Christine
AU  - Czech, Thomas
AU  - Kool, Marcel
AU  - Peyrl, Andreas
TI  - Improved Long-Term Survival of Patients with Recurrent Medulloblastoma Treated with a 'MEMMAT-like' Metronomic Antiangiogenic Approach.
JO  - Cancers
VL  - 14
IS  - 20
SN  - 2072-6694
CY  - Basel
PB  - MDPI
M1  - DKFZ-2022-02563
SP  - 5128
PY  - 2022
AB  - Medulloblastoma (MB) recurrence is usually incurable despite intensive therapy including high-dose chemotherapy. An evolving alternative approach to conventional chemotherapy aims at interfering with tumor angiogenesis at different levels. We report on a novel combinatorial metronomic antiangiogenic approach. The study is a retrospective observational study of 29 consecutive patients with first or multiple recurrences prospectively treated according to the MEMMAT strategy ('MEMMAT-like') before the formal protocol (MEMMAT; ClinicalTrials.gov Identifier: NCT01356290) started. The study period was 11/2006 to 06/2016. Treatment consisted of daily oral thalidomide, fenofibrate, celecoxib, and alternating 21-day cycles of low-dose oral etoposide and cyclophosphamide supplemented by IV bevacizumab and intraventricular therapy consisting of alternating etoposide and liposomal cytarabine. Median overall survival (OS) after recurrence for the whole group was 29.5 months, OS was 48.3 ± 9.3
KW  - MEMMAT (Other)
KW  - antiangiogenic therapy (Other)
KW  - bevacizumab (Other)
KW  - intraventricular therapy (Other)
KW  - low-dose oral therapy (Other)
KW  - medulloblastoma recurrence (Other)
KW  - metronomic therapy (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:36291912
DO  - DOI:10.3390/cancers14205128
UR  - https://inrepo02.dkfz.de/record/182306
ER  -